Intravenous Administration of Toll-Like Receptor Inhibitory Peptide 1 is Effective for the Treatment of Systemic Lupus Erythematosus in a Mus musculus Model

OBJECTIVE: Systemic lupus erythematosus (SLE) is a common chronic autoimmune inflammatory disease According to recent studies, signaling through Toll-like receptor (TLR) protein, which promotes the production of inflammatory cytokines, leads to the development of SLE TLR-inhibitory peptide 1 (TIP1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Wook-Young, Lee, Sung-Min, Lee, Sang-Won, Son, In-Ok, Choi, Sangdun, Suh, Chang-Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Rheumatology 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324895/
https://www.ncbi.nlm.nih.gov/pubmed/37475994
http://dx.doi.org/10.4078/jrd.2021.28.3.133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324895/
https://www.ncbi.nlm.nih.gov/pubmed/37475994
http://dx.doi.org/10.4078/jrd.2021.28.3.133

Ejemplares similares